Li D, et al. - The efficacy and safety of sodium-glucose co-transporter 2 (SGLT2) inhibitors plus a dipeptidyl peptidase-4 (DPP-4) inhibitor were comprehensively investigated by authors in patients with type 2 diabetes mellitus (T2DM). It was observed that the addition of a DPP-4 inhibitor to an SGLT2 inhibitor could reduce HbA1c by -0.31%, fasting plasma glucose [FPG] by -8.94 mg/dL, total cholesterol (TC) by -1.48% and triglycerides by -3.25%. Data reported similar adverse events for the combination therapy, with the exception of genital infection vs DPP-4 inhibitor and consistent genital infection vs an SGLT2 inhibitor.